AEFI case reporting slows as vaccinations pick up, shows data

According to the latest data, 569 AEFI cases were reported between August and November 16

COVID Oxford study
An AEFI is any untoward medical occurrence which follows immunisation and which does not necessarily have a causal relationship with the usage of the vaccine (Representational Image: Bloomberg)
Sohini Das
2 min read Last Updated : Nov 19 2021 | 1:43 AM IST
A recent review of adverse events following immunisation (AEFI) reporting during the Covid-19 pandemic (till July 2021) showed the overall reporting of AEFI cases (per 100,000 population) declined as vaccinations expanded to include more sections of the population.

According to the latest data, 569 AEFI cases were reported between August and November 16.

An AEFI is any untoward medical occurrence which follows immunisation and which does not necessarily have a causal relationship with the usage of the vaccine. Week-wise data from the health ministry showed that on Week 3 since Covid-19 vaccinations started in January, 5,105 AEFI cases were reported.



If one measures this as AEFI cases reported per 100,000 of vaccine doses administered the number comes to 322. By Week 9, overall AEFI case reporting dipped to 329 cases, and only 5 cases per 100,000 vaccine doses administered. By Week 29, only 249 cases were reported, working out to be two cases per 100,000 vaccine doses administered by then.
India slowly opened up vaccinations to more sections of the population — on March 1 for those above 60 years and with people with serious co-morbidities, from April 1, vaccination was opened for those above 45 years, and from May 1 everyone above 18 years was allowed to take a Covid-19 jab.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineCoronavirus Tests

Next Story